TICKERNERD
Menu
MRVIMRVIHealthcare · Biotechnology

MRVI Stock Forecast: Maravai Lifesciences Holdings, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$6.52
−3.12% on the day

The 9 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. hold a median 12-month price target of $7.5 — +15.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.4B
Ticker Nerd rank
87 / 100
Median analyst target
$7.50
Analysts covering
9
Revenue$51.4M+8.5% y/y
Operating income−$15.1M
Net income−$21.6M
Free cash flow$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.5%
1M
+12.2%
YTD
+100.6%
1Y
+133.7%
From 52W high
−27.6%
From 52W low
+144.2%
$2.67
$9.00
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MRVI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Maravai Lifesciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Momentum
90
Accruals
87
Issuance
84
Revisions
69
Value
43
Size
38
Quality
37
Volatility
36

Growth (95): Sales and profits are climbing, and climbing faster than before.

Volatility (36): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MRVI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MRVI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26MRVIHigh $8.00Median $7.50Low $6.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
5 Buy4 Hold0 Sell
Low $6.50Median $7.50High $8.00

The green dot is the last close — the median target sits +15.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026UBSMaintainsNeutral$2.50 → $8.00
7 Aug 2026Wells FargoMaintainsOverweight$5.50 → $6.50
7 Aug 2026Wells FargoMaintainsOverweight—
8 May 2026Wells FargoMaintainsOverweight$4.50 → $5.50
8 May 2026Wells FargoMaintainsOverweight—
15 Dec 2025Wells FargoMaintainsOverweight—
12 Aug 2025Craig-HallumMaintainsBuy—
12 Aug 2025RBC CapitalMaintainsOutperform—
13 May 2025BairdMaintainsNeutral—
13 May 2025Craig-HallumMaintainsBuy—
25 Mar 2025Morgan StanleyMaintainsEqual-Weight—
21 Mar 2025UBSMaintainsNeutral—
3 Mar 2025B of A SecuritiesMaintainsBuy—
26 Feb 2025BairdDowngradeNeutral—
5 Dec 2024Goldman SachsDowngradeSell—
14 Nov 2024Wolfe ResearchInitiatesPeer Perform—
8 Nov 2024BairdMaintainsOutperform—
8 Nov 2024RBC CapitalMaintainsOutperform—
8 Nov 2024William BlairDowngradeMarket Perform—
8 Oct 2024Goldman SachsMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRVI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MRVI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Maravai Lifesciences Holdings, Inc. returned +133.7% against +17.5% for the S&P 500, dividends included.

MRVI vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26MRVIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MRVI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
2
Fundamentals

Maravai Lifesciences Holdings, Inc. (MRVI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
28.4×

Cheaper than 27% of US stocks

Price / sales
11.6×

Cheaper than 13% of US stocks

Price / book
4.8×

Cheaper than 22% of US stocks

EV / EBITDA
−64.4×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
8.5%

Higher than 48% of US stocks

Earnings growth (YoY)
8.5%

Higher than 46% of US stocks

Gross margin
40.1%

Higher than 50% of US stocks

Operating margin
−29.4%

Higher than 20% of US stocks

Net margin
−37.1%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−33.0%

Higher than 26% of US stocks

Return on assets
−5.7%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Maravai Lifesciences Holdings, Inc. (MRVI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Maravai Lifesciences Holdings, Inc. has a market value of $2.4B and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $208.8M. The latest quarter grew 8.5% year on year.

  • Net income over the same four quarters: −$136.1M, a −65.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.52.

  • Free cash flow in the twelve months to 30 June 2026: −$35.8M.

  • Shares outstanding: 148.9M.

  • Trailing P/E: 28.4×; forward P/E: −62.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Maravai Lifesciences Holdings, Inc. employs 415 people — $503K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MRVI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MRVIMaravai Lifesciences Holdings, Inc.$2.4B
87
RXRXRecursion Pharmaceuticals, Inc.$1.7B
44
DMRADamora Therapeutics, Inc.$1.7B
45
NTLAIntellia Therapeutics, Inc.$1.6B
51
FBRXForte Biosciences, Inc.$1.6B
—
FTREFortrea Holdings, Inc.$1.6B
97
KARDKardigan, Inc.$1.7B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Maravai Lifesciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MRVI news & analysis

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel

Seeking Alpha · 2 Sept 2026positive

Maravai LifeSciences is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, with Q2 2026 marking a profitability inflection as gross margins rose to 40.1% and Adjusted EBITDA turned positive. The company's TriLink GMP enzyme facility and ModTail technology are strengthening customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.

Why it matters — MRVI watchers would care because the company has reached a profitability inflection and is building a diversified, recurring revenue base across the RNA consumables workflow.

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Maravai LifeSciences Holdings, Inc. released its Q2 2026 earnings call transcript, covering the company's second-quarter 2026 financial results and management commentary. The transcript was published via Seeking Alpha.

Why it matters — MRVI watchers would review the earnings call transcript for management's own account of the quarter's financial performance and outlook.

Maravai LifeSciences Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Maravai LifeSciences reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.

Why it matters — MRVI watchers would care because the company's improved profitability and raised adjusted EBITDA forecast signal stronger underlying financial performance for the year.

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Maravai LifeSciences Holdings reported a second-quarter loss of $0.02 per share, narrower than the Zacks Consensus Estimate of a $0.05 loss and improved from a $0.08 loss in the same quarter a year ago.

Why it matters — The improved, better-than-expected quarterly loss may indicate strengthening underlying performance for MRVI watchers.

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Business Wire · 6 Aug 2026positive

Maravai LifeSciences reported second-quarter 2026 results with revenue of $51.4 million, a net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million. The company also raised its full-year 2026 Adjusted EBITDA guidance to $33 million to $35 million.

Why it matters — The raised full-year Adjusted EBITDA guidance signals improved expectations for Maravai's performance, offering a key indicator for investors tracking the company's financial trajectory.

FAQ

Frequently asked questions about MRVI stock

What is the MRVI stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. have a median 12-month price target of $7.5, with estimates ranging from $6.5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MRVI stock a buy right now?

Of the 9 analysts covering Maravai Lifesciences Holdings, Inc., 5 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maravai Lifesciences Holdings, Inc. 87 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MRVI?

As at 12 Sept 2026, Maravai Lifesciences Holdings, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will MRVI stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +15.0% from the last close, and Ticker Nerd's factor model ranks Maravai Lifesciences Holdings, Inc. 87 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MRVI stock forecast for 2030?

No analyst covering Maravai Lifesciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $8 over the next 12 months.

How has MRVI stock performed over the past year?

Maravai Lifesciences Holdings, Inc. returned +133.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Maravai Lifesciences Holdings, Inc. do?

Maravai LifeSciences Holdings, Inc. Class A Common Stock represents ownership in Maravai LifeSciences Holdings, Inc., a life sciences company focused on products and services that support drug development, vaccine creation, cell and gene therapy research, and diagnostics.

What is the latest news on MRVI?

The most recent item we track (Seeking Alpha, 2 Sept 2026): "Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel". Maravai LifeSciences is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, with Q2 2026 marking a profitability inflection as gross margins rose to 40.1% and Adjusted EBITDA turned positive. The company's TriLink GMP enzyme facility and ModTail technology are strengthening customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.

Company

About Maravai Lifesciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. Class A Common Stock represents ownership in Maravai LifeSciences Holdings, Inc., a life sciences company focused on products and services that support drug development, vaccine creation, cell and gene therapy research, and diagnostics. The company serves biopharmaceutical, biotechnology, and research customers through specialized offerings in nucleic acid production and biologics safety testing. Its product portfolio includes reagents, enzymes, nucleic acid tools, and analytical services used across molecular biology, genomics, and bioprocessing workflows. Maravai LifeSciences plays a role in the broader healthcare and life sciences market by supplying critical inputs that help enable laboratory research, therapeutic development, and quality testing across the drug development process. The company is headquartered in San Diego, California, and its business is organized around current operating segments that address research and production needs in advanced biologics and diagnostics.

CEO Mr. Bernd Brust · 415 employees · United States · https://www.maravai.com